39. Randomized and non-randomized controlled cohort studies for the prevention of cancer with a mistletoe extract for myomas, endometrioses and cervix dysplasia.
Design: A matched-pair study design involving, respectively, one randomized and one non-randomized controlled prospective cohort study on female patients with myomas, endometrioses and cervix dysplasia. The matching criteria encompass diagnosis parameters, age at first diagnosis and year of first diagnosis.
Setting: Recruitment of subjects from: the Heidelberg Prospective Intervention Study, six hospital and after-care institutions in Germany, and the Institute for Preventive Medicine in Heidelberg.
Study duration: Prospective data recording between 1973 and 1998. Concluding follow-up from 1999 to 2001.
Patients: Female patients with myomas (subserous, submucous, intramural), endometrioses or cervix dysplasia (PAP III and IV).
Tested medication: Iscador[R] mistletoe preparation as complementary therapy to standard treatment.
Target criteria: Cancer incidence, tumour-related survival and overall survival.
Results: In the randomized studies, the Iscador group of patients with endometrioses and cervix dysplasia showed significantly lower incidence of cancer and a tendency to longer tumour-related survival periods; in the case of myomas no significant effects were found. In the non-randomized studies there was significantly lower incidence of cancer and significantly longer tumour-related survival in Iscador patients with myomas and endometrioses; no effects were found for cervix dysplasia.
Conclusions: For endometrioses, the randomized and non-randomized study demonstrated consistently positive effects on cancer incidence and tumour-related survival in the Iscador group. For cervix dysplasia the positive effects in the randomized study were not confirmed by the non-randomized study. No effect on overall survival was found. In the case of endometrioses, in particular, mistletoe therapy may have a positive influence on incidence of cancer and tumour-related survival.
Keywords: Viscum album L.; Iscador; Cancer incidence; Survival; Endometriosis; Myoma; Cervix dyplasia
R. Ziegler (a,*), R. Grossarth-Maticek (b)
(a) Hiscia Institute, Verein fur Krebsforschung, 4144 Arlesheim, Switzerland
(b) Institute for Preventive Medicine, European Center for Peace and Development (ECPD), 67117 Heidelberg, Germany
*Corresponding author. Tel.: +41 61 706 72 45; fax: +41 61 706 72 00.
E-mail address: email@example.com (R. Ziegler).
|Printer friendly Cite/link Email Feedback|
|Author:||Ziegler, R.; Grossarth-Maticek, R.|
|Publication:||Phytomedicine: International Journal of Phytotherapy & Phytopharmacology|
|Date:||Oct 1, 2007|
|Previous Article:||38. Treatment with a fermented mistletoe (Viscum album L.) extract as part of long-term supportive care in patients with primary non-metastatic...|
|Next Article:||40. Self-cleavage of mistletoe lectin I into the A and B subunits by thiol-disulfide exchange reaction.|